Abstract
Unveiling body composition as prognostic factor in metastatic cancer patients (PT) treated with molecularly-targeted agents (MTA) or immunotherapy (IO)
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
